Jewell Christopher M 4
4 · Cartesian Therapeutics, Inc. · Filed Jan 13, 2025
Insider Transaction Report
Form 4
Jewell Christopher M
Chief Scientific Officer
Transactions
- Exercise/Conversion
Common Stock
2025-01-10$3.23/sh+9,000$29,070→ 62,490 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-01-10−9,000→ 67,432 totalExercise: $3.23Exp: 2033-01-15→ Common Stock (9,000 underlying)
Footnotes (2)
- [F1]The option is currently exercisable for an additional 51,089 shares of Common Stock and becomes exercisable for an additional 2,969 shares of Common Stock each month until it is fully exercisable on June 16, 2025.
- [F2]On November 13, 2023, the Issuer acquired the private Delaware corporation which was then known as Cartesian Therapeutics, Inc. ("Old Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. Options to purchase Old Cartesian common stock held by the reporting person were converted into options to purchase shares of the Issuer's Series A Preferred Stock in connection with the merger. On April 8, 2024, these options previously exercisable for shares of Series A Preferred Stock became exercisable solely for shares of the Issuer's Common Stock.